Coherus Identifies Stealing Amgen’s Crown As Pegfilgrastim Market Leader
Plans To Avoid ‘Resorting To Disproportionate Discounting’ Of Other Biosimilars
With its Udenyca pegfilgrastim biosimilar sales plunging in 2021 amid pricing and volume pressures, Coherus is looking to balance price and share trade-offs in 2022 before the intended launch of its proposed on-body injector device next year – in turn aiming to become the eventual pegfilgrastim market leader.
